Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1991 1
1994 2
2005 1
2012 1
2013 1
2014 2
2016 3
2017 2
2018 2
2019 8
2020 7
2021 12
2022 9
2023 15
2024 22
2025 33

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

113 results

Results by year

Filters applied: . Clear all
Page 1
A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL.
Zanetti SR, Velasco-Hernandez T, Gutierrez-Agüera F, Díaz VM, Romecín PA, Roca-Ho H, Sánchez-Martínez D, Tirado N, Baroni ML, Petazzi P, Torres-Ruiz R, Molina O, Bataller A, Fuster JL, Ballerini P, Juan M, Jeremias I, Bueno C, Menéndez P. Zanetti SR, et al. Among authors: bataller a. Mol Ther. 2022 Feb 2;30(2):550-563. doi: 10.1016/j.ymthe.2021.08.033. Epub 2021 Sep 1. Mol Ther. 2022. PMID: 34478871 Free PMC article.
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study.
Bazinet A, Garcia-Manero G, Short N, Alvarado Y, Bataller A, Abuasab T, Islam R, Montalbano K, Issa G, Maiti A, Yilmaz M, Jain N, Masarova L, Kornblau S, Jabbour E, Montalban-Bravo G, Rausch CR, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Ravandi F. Bazinet A, et al. Among authors: bataller a. Lancet Haematol. 2024 Apr;11(4):e276-e286. doi: 10.1016/S2352-3026(24)00033-4. Epub 2024 Mar 4. Lancet Haematol. 2024. PMID: 38452788 Free PMC article. Clinical Trial.
Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial.
Bazinet A, Kantarjian H, Bataller A, Pemmaraju N, Borthakur G, Chien K, Alvarado Y, Bose P, Jabbour E, Yilmaz M, DiNardo C, Issa G, Montalban-Bravo G, Short N, Sasaki K, Bull-Linderman D, Daver N, Garcia-Manero G, Ravandi F, Kadia T. Bazinet A, et al. Among authors: bataller a. Lancet Haematol. 2024 Apr;11(4):e287-e298. doi: 10.1016/S2352-3026(24)00034-6. Lancet Haematol. 2024. PMID: 38548404 Free PMC article. Clinical Trial.
Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
Bataller A, Loghavi S, Gerstein Y, Bazinet A, Sasaki K, Chien KS, Hammond D, Montalban-Bravo G, Borthakur G, Short N, Issa GC, Kadia TM, Daver N, Tang G, Quesada A, Patel KP, Ravandi F, Fiskus W, Mill CP, Kantarjian HM, Bhalla K, Garcia-Manero G, Oran B, DiNardo CD. Bataller A, et al. Am J Hematol. 2023 Nov;98(11):1780-1790. doi: 10.1002/ajh.27070. Epub 2023 Sep 4. Am J Hematol. 2023. PMID: 37665752 Free PMC article.
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.
Kadia TM, Jen WY, Bataller A, Bazinet A, Borthakur G, Jabbour E, Qiao W, Short NJ, Takahashi K, Issa GC, DiNardo CD, Montalban-Bravo G, Pemmaraju N, Tran A, Bharathi V, Loghavi S, Alousi AM, Popat U, Daver NG, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: bataller a. Am J Hematol. 2025 Aug;100(8):1365-1373. doi: 10.1002/ajh.27723. Epub 2025 May 22. Am J Hematol. 2025. PMID: 40401707 Clinical Trial.
Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax.
Bataller A, Bazinet A, DiNardo CD, Maiti A, Borthakur G, Daver NG, Short NJ, Jabbour EJ, Issa GC, Pemmaraju N, Yilmaz M, Montalban-Bravo G, Takahashi K, Loghavi S, Garcia-Manero G, Ravandi F, Kantarjian HM, Kadia TM. Bataller A, et al. Blood Adv. 2024 Feb 27;8(4):927-935. doi: 10.1182/bloodadvances.2023011757. Blood Adv. 2024. PMID: 38113472 Free PMC article.
A novel chimeric antigen receptor T-cell therapy targeting CD84 for the treatment of acute myeloid and T-cell lymphoblastic leukemias.
Pérez-Amill L, Armand-Ugón M, Val-Casals M, Martín-Herreros B, Álamo JR, Peña S, Frigola G, Altuna A, Santos C, Guijarro F, Minguela A, Bataller À, Casanovas-Albertí B, Uribe-Herranz M, Navarro I, Guerreiro M, Sánchez-Martínez D, Tirado N, Velasco-Hernandez T, Menéndez P, Martínez A, Rovira M, Colomer D, González-Navarro EA, Esteve J, Urbano-Ispizua Á, Montesinos P, Delgado J, Juan M, Klein-González N. Pérez-Amill L, et al. Among authors: bataller a. Leukemia. 2025 Oct;39(10):2432-2441. doi: 10.1038/s41375-025-02705-4. Epub 2025 Aug 6. Leukemia. 2025. PMID: 40770072 Free PMC article.
Integrative single-cell multi-omics of CD19-CARpos and CARneg T cells suggest drivers of immunotherapy response in B cell neoplasias.
Guerrero-Murillo M, Rill-Hinarejos A, Trincado JL, Bataller A, Ortiz-Maldonado V, Benítez-Ribas D, Español-Rego M, González-Navarro EA, Martínez-Cibrián N, Marchese D, Martín-Martín L, Martín García-Sancho A, Rives S, Heyn H, Juan M, Urbano-Ispizúa Á, Delgado J, Orfao A, Mereu E, Bueno C, Menendez P. Guerrero-Murillo M, et al. Among authors: bataller a. Cell Rep Med. 2024 Nov 19;5(11):101803. doi: 10.1016/j.xcrm.2024.101803. Epub 2024 Oct 28. Cell Rep Med. 2024. PMID: 39471818 Free PMC article.
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Senapati J, Kantarjian HM, Bazinet A, Reville P, Short NJ, Daver N, Borthakur G, Bataller A, Jabbour E, DiNardo C, Haddad F, Sasaki K, Popat U, Oran B, Alousi AM, Loghavi S, Shpall E, Garcia-Manero G, Ravandi F, Kadia TM. Senapati J, et al. Among authors: bataller a. Cancer. 2024 Oct 1;130(19):3333-3343. doi: 10.1002/cncr.35388. Epub 2024 May 29. Cancer. 2024. PMID: 38809547 Clinical Trial.
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia.
Silbert SK, Rankin AW, Hoang CN, Semchenkova A, Myers RM, Zerkalenkova E, Wang HW, Kovach AE, Yuan CM, Delgado Colon D, Vasseur L, Bataller A, John S, Utley Lyons K, Friedes B, Alonso-Saladrigues A, Abdel-Azim H, Balducci E, Aljudi AA, Balsat M, Biery DN, Chamdin A, Chang BH, Cuevo RS, De Moerloose B, Dickens DS, Duffner U, Duployez N, El Chaer F, Elliott MA, Escherich G, Fernandes S, Fitzjohn MR, Gahvari Z, Grupp SA, He RR, Harrison C, Hergott CB, Hsieh EM, Kim AS, Kuo DJ, Larson DP, Lee BJ, Leguay T, Lindsley RC, Mangaonkar AA, Mezger K, Pacenta HL, Pan J, Provost M, Puri L, Raikar SS, Martinez A, Bristol I, Murphy K, Reiman L, Redell M, Reed K, Roth-Guepin G, Rubinstein J, Savaşan S, Schafernak K, Stevens A, Talleur A, Torres Carapia N, Vargaftig J, Vatsayan A, Wölfl M, Zhao L, Rives S, Fabrizio VA, Sasaki K, Aldoss I, Boissel N, Rheingold SR, Davis KL, Ghorashian S, Jacoby E, Popov A, Lamble AJ, Shah NN. Silbert SK, et al. Among authors: bataller a. Blood. 2025 Jul 24;146(4):437-455. doi: 10.1182/blood.2024026655. Blood. 2025. PMID: 40193715 Free PMC article.
113 results